Investigation Overview
December 12, 2014 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST), was announced concerning whether the takeover of Cubist Pharmaceuticals Inc by Merck for $102 per share is unfair to NASDAQ:CBST stockholders. The investigation by a law firm concerns whether certain officers and directors of Cu...
You must register (for free) or login to view the entire investigation.